MC
XLO icon

Merck & Co’s Xilio Therapeutics XLO Stock Holding History

Merck & Co’s Portfolio XLO Stock Details XLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$891K Sell
105,982
-1
-0% -$8 0.26% 11
2025
Q4 		$950K Hold
105,983
– – 0.34% 9
2025
Q3 		$1.25M Hold
105,983
– – 0.55% 10
2025
Q2 		$1.01M Hold
105,983
– – 0.47% 10
2025
Q1 		$1.07M Hold
105,983
– – 0.65% 10
2024
Q4 		$1.42M Buy
+105,983
New +$1.46M 0.55% 9

Other funds holding XLO

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AIIC
AJU IB Investment Company Seoul, South Korea $30.5M AUM 128.96% 1-Year Est. Return

Merck & Co's XLO Position: Q1 2026 in Review

Merck & Co reduced its Xilio Therapeutics (XLO) stake by 0% in Q1 2026, selling an estimated $8 and leaving 105,982 shares worth $891K. The position accounts for 0.26% of the portfolio, ranked #11.

Merck & Co first reported a position in XLO in Q4 2024 and has held it in 6 quarters since. The position peaked at $1.42M in Q4 2024. 24 funds tracked by Wall St. Rank hold XLO as of Q1 2026.

  • Merck & Co held 105,982 shares of Xilio Therapeutics worth $891K as of Q1 2026.
  • Merck & Co sold 1 Xilio Therapeutics share in Q1 2026, an estimated $8.
  • Xilio Therapeutics made up 0.26% of Merck & Co's portfolio in Q1 2026, its #11 holding.
  • Merck & Co first reported a position in Xilio Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • Merck & Co's Xilio Therapeutics position peaked at $1.42M in Q4 2024.
  • 24 funds tracked by Wall St. Rank held Xilio Therapeutics as of Q1 2026.

Based on Merck & Co's 13F filing for Q1 2026, filed 13 May 2026.